Niagen Bioscience
NAGE
42 hedge funds and large institutions have $14.2M invested in Niagen Bioscience in 2017 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 12 increasing their positions, 11 reducing their positions, and 12 closing their positions.
9% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 11
4% less capital invested
Capital invested by funds: $14.7M → $14.2M (-$576K)
1.51% less ownership
Funds ownership: 8.36% → 6.85% (-1.5%)
9% less funds holding
Funds holding: 46 → 42 (-4)
25% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$311K |
| 2 |
VF
Virtu Financial
New York
|
+$231K |
| 3 |
PHS
Pekin Hardy Strauss
Chicago,
Illinois
|
+$128K |
| 4 |
TDC
Thompson Davis & Co
Richmond,
Virginia
|
+$109K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$79.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$698K |
| 2 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$406K |
| 3 |
ECM
Element Capital Management
New York
|
-$380K |
| 4 |
LP
LMR Partners
London,
United Kingdom
|
-$347K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$249K |
NAGE Hedge Fund Activity: Q3 2017 in Review
42 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Niagen Bioscience (NAGE) for Q3 2017, worth a combined $14.2M — down 3.9% from $14.7M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of NAGE and 9 opened new positions — a net loss of 3 holders — while 11 trimmed existing stakes and 12 added.
The largest buyer was Vanguard Group, adding an estimated $311K. The largest seller was Goldman Sachs, exiting entirely with an estimated $698K sold.
- 42 institutional investors held Niagen Bioscience (NAGE) as of Q3 2017, down from 46 in Q2 2017.
- Funds reported $14.2M of Niagen Bioscience stock for Q3 2017, down 3.9% quarter-over-quarter.
- 9 funds opened new Niagen Bioscience positions in Q3 2017 and 12 closed out, a net change of -3 holders.
- The largest Niagen Bioscience buyer in Q3 2017 was Vanguard Group, an estimated $311K added.
- The largest Niagen Bioscience seller in Q3 2017 was Goldman Sachs, an estimated $698K sold.
Based on aggregated 13F filings for Q3 2017.